Efficacy of panitumumab plus irinotecan versus cetuximab plus irinotecan in patients with wild-type KRAS exon2 metastatic colorectal cancer previously treated with bevacizumab within 6 months.

被引：1
|
作者：
Hayashi, Kaori
Mitani, Seiichiro
Taniguchi, Hiroya
Hamauchi, Satoshi
Sugiyama, Keiji
Tsushima, Takahiro
Honda, Kazunori
Todaka, Akiko
Masuishi, Toshiki
Yokota, Tomoya
Narita, Yukiya
Machida, Nozomu
Kadowaki, Shigenori
Fukutomi, Akira
Ura, Takashi
Onozawa, Yusuke
Ando, Masashi
Yasui, Hirofumi
Muro, Kei
Yamazaki, Kentaro
机构：
[1] Shizuoka Canc Ctr, Div Gastrointestinal Oncol, Shizuoka, Japan
[2] Aichi Canc Ctr Hosp, Dept Clin Oncol, Nagoya, Aichi, Japan
[3] Aichi Canc Ctr Hosp, Nagoya, Aichi, Japan
[4] Shizuoka Canc Ctr Hosp, Div Med Oncol, Shizuoka, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷 / 04期
关键词：
D O I：
10.1200/JCO.2017.35.4_suppl.800
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
800
引用
收藏
页数：1
相关论文
共 50 条
  • [41] A PHASE II STUDY OF CETUXIMAB PLUS IRINOTECAN/S-1 AS FIRST-LINE TREATMENT IN KRAS WILD-TYPE METASTATIC COLORECTAL CANCER
    Masuishi, T.
    Sakai, Y.
    Matsui, T.
    Nakamura, R.
    Anzai, S.
    Suzuki, Y.
    Kobori, I.
    Fukami, Y.
    Suzuki, K.
    Tazawa, J.
    ANNALS OF ONCOLOGY, 2013, 24
  • [42] Efficacy of Panitumumab Plus FOLFIRI Versus FOLFIRI Alone in Patients With Wild-Type (WT) KRas Metastatic Colorectal Cancer (mCRC) Treated With Prior Oxaliplatin or Bevacizumab Regimens: Results From 20050181
    Price, T.
    Peeters, M.
    Strickland, A.
    Ciuleanu, T. E.
    Scheithauer, W.
    O'Reilly, S.
    Keane, M.
    Spigel, D.
    Tian, Y.
    Kartik, K.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S431 - S432
  • [43] Sequential cetuximab/bevacizumab therapy is associated with improved outcomes in patients with wild-type KRAS exon 2 metastatic colorectal cancer
    Hsu, Hung-Chih
    Liu, Yu-Chun
    Wang, Chuang-Wei
    Chou, Wen-Chi
    Hsu, Yu-Jen
    Chiang, Jy-Ming
    Lin, Yung-Chang
    Yang, Tsai-Sheng
    CANCER MEDICINE, 2019, 8 (07): : 3437 - 3446
  • [44] A Prospective, Multicenter Phase II Study of the Efficacy and Feasibility of 15-minute Panitumumab Infusion Plus Irinotecan for Oxaliplatin- and Irinotecan-refractory, KRAS Wild-type Metastatic Colorectal Cancer (Short Infusion of Panitumumab Trial)
    Akiyoshi, Kohei
    Hamaguchi, Tetsuya
    Yoshimura, Kenichi
    Takahashi, Naoki
    Honma, Yoshitaka
    Iwasa, Satoru
    Takashima, Atsuo
    Kato, Ken
    Yamada, Yasuhide
    Onodera, Hisashi
    Takeshita, Shigeyuki
    Yasui, Hisateru
    Sakai, Gen
    Akatsuka, Sotaro
    Ogawa, Kohei
    Horita, Yosuke
    Nagai, Yushi
    Shimada, Yasuhiro
    CLINICAL COLORECTAL CANCER, 2018, 17 (01) : E83 - E89
  • [45] Biweekly cetuximab plus irinotecan as second-line chemotherapy for patients with irinotecan-refractory and KRAS wild-type metastatic colorectal cancer according to epidermal growth factor receptor expression status
    Myoung Joo Kang
    Yong Sang Hong
    Kyu-pyo Kim
    Sun Young Kim
    Ji Yeon Baek
    Min-Hee Ryu
    Jae-Lyun Lee
    Heung Moon Chang
    Mi-Jung Kim
    Hee Jin Chang
    Yoon-Koo Kang
    Tae Won Kim
    Investigational New Drugs, 2012, 30 : 1607 - 1613
  • [46] Biweekly cetuximab plus irinotecan as second-line chemotherapy for patients with irinotecan-refractory and KRAS wild-type metastatic colorectal cancer according to epidermal growth factor receptor expression status
    Kang, Myoung Joo
    Hong, Yong Sang
    Kim, Kyu-pyo
    Kim, Sun Young
    Baek, Ji Yeon
    Ryu, Min-Hee
    Lee, Jae-Lyun
    Chang, Heung Moon
    Kim, Mi-Jung
    Chang, Hee Jin
    Kang, Yoon-Koo
    Kim, Tae Won
    INVESTIGATIONAL NEW DRUGS, 2012, 30 (04) : 1607 - 1613
  • [47] PEAK: A Randomized, Multicenter Phase II Study of Panitumumab Plus Modified Fluorouracil, Leucovorin, and Oxaliplatin (mFOLFOX6) or Bevacizumab Plus mFOLFOX6 in Patients With Previously Untreated, Unresectable, Wild-Type KRAS Exon 2 Metastatic Colorectal Cancer
    Schwartzberg, Lee S.
    Rivera, Fernando
    Karthaus, Meinolf
    Fasola, Gianpiero
    Canon, Jean-Luc
    Hecht, J. Randolph
    Yu, Hua
    Oliner, Kelly S.
    Go, William Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (21) : 2240 - +
  • [48] A phase II study of panitumumab plus irinotecan for metastatic colorectal cancer with wild KRAS, resistant to fluoropyrimidine, oxaliplatin, and irinotecan in Japanese (OGSG1001).
    Taira, Koichi
    Yoshida, Motoki
    Sugimoto, Naotoshi
    Kii, Takayuki
    Kuwakado, Shin
    Fukunaga, Mutsumi
    Hasegawa, Hiroko
    Kato, Takeshi
    Miyake, Yasuhiro
    Hata, Taishi
    Tokunaga, Yukihiko
    Takeda, Koji
    Daga, Haruko
    Yoshinami, Tetsuhiro
    Shimokawa, Toshio
    Sakai, Daisuke
    Kurokawa, Yukinori
    Satoh, Taroh
    Tsujinaka, Toshimasa
    Furukawa, Hiroshi
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [49] Randomized phase II study of regorafenib followed by cetuximab versus reverse sequence for wild-type KRAS metastatic colorectal cancer previously treated with fluoropyrimidine, oxaliplatin, and irinotecan (REVERCE).
    Shitara, Kohei
    Yamazaki, Kentaro
    Uetake, Hiroyuki
    Kato, Takeshi
    Oki, Eiji
    Yamanaka, Takeharu
    Ohashl, Yasuo
    Yoshino, Takayukl
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [50] Association of FcgRIIa and FcgRIIIa polymorphisms and kras mutations with clinical outcome in patients with metastatic colorectal cancer treated with cetuximab plus irinotecan
    Bibeau, F.
    Crapez, E.
    Di Fiore, F.
    Thezenas, S.
    Sabourin, J.
    Lamy, A.
    Frebourg, T.
    Michel, P.
    Ychou, M.
    Boissiere, F.
    ANNALS OF ONCOLOGY, 2008, 19 : 27 - 27
12345